Payment overview · 2025
General Payments
$320.92
18 reported records · 9 companies
Healthcare provider profile · identity verified
Paul Wells James, DNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · LAKE CITY, SC · NPI 1720629512
Verified facts
What the public records show
CMS Open Payments records show Paul Wells James, DNP received $320.92 in general payments during 2025 across 18 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $84.69 | 26.4% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $62.33 | 19.4% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $39.16 | 12.2% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $36.86 | 11.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.93 | 8.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.38 | 6.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.23 | 5.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.68 | 5.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.66 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $320.92 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $39.16 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $36.86 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.29 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.90 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $29.04 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $26.93 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 184 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
184 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 341 | 113 |
| Atorvastatin Calcium | Atorvastatin Calcium | 320 | 90 |
| Jardiance | Empagliflozin | 184 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 182 | 63 |
| Metformin Hcl | Metformin Hcl | 118 | 30 |
| Prednisone | Prednisone | 111 | 101 |
| Losartan Potassium | Losartan Potassium | 104 | 40 |
| Omeprazole | Omeprazole | 104 | 25 |
| Valsartan | Valsartan | 92 | 34 |
| Gabapentin | Gabapentin | 90 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 83 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 80 | 22 |
| Metformin Hcl Er | Metformin Hcl | 73 | 20 |
| Lisinopril | Lisinopril | 71 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 69 | 20 |
| Montelukast Sodium | Montelukast Sodium | 61 | 17 |
| Meloxicam | Meloxicam | 60 | 17 |
| Carvedilol | Carvedilol | 59 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 13 |
| Levothyroxine Sodium | Levothyroxine Sodium | 48 | 12 |
| Allopurinol | Allopurinol | 47 | 14 |
| Eliquis | Apixaban | 45 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 24 |
| Trulicity | Dulaglutide | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 43 | suppressed |
| Ozempic | Semaglutide | 42 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 16 |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Chlorthalidone | Chlorthalidone | 38 | 15 |
| Famotidine | Famotidine | 38 | suppressed |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Furosemide | Furosemide | 36 | 17 |
| Glipizide Er | Glipizide | 34 | suppressed |
| Tradjenta | Linagliptin | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 29 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 24 |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 24 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Azithromycin | Azithromycin | 20 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Simvastatin | Simvastatin | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $320.92 · 18 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, Cologuard Collection Kit, GEMTESA, JARDIANCE, MOUNJARO, OTEZLA, REPATHA, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error